BDX
BECTON DICKINSON & CO
NYSE: BDX · Franklin Lakes, NJ · Healthcare
$156.69-1.95 (-1.23%)Closed
Market Cap$44.62B
Cash$740.0Mmost recent
Runwayprofitable
P/E (TTM)26.9EPS $5.82
52-Wk Range$126.85 – $184.21
Avg Volume3.1M3-month
Price & Trading Activity
Daily close with catalyst overlays and trading volume
$156.69-11.3%
Pipeline
Drug candidates sponsored by BECTON DICKINSON & · ClinicalTrials.gov
| Phase | Drug / Candidate | Indications | Status | Next Completion | Trials | |
|---|---|---|---|---|---|---|
| Phase 2 | Regular insulin (Humulin) | Diabetes Mellitus, Type 1 | Completed | 2007-12past | 1 | |
| Phase 1 | Unnamed | Diabetes Mellitus, Type 1+1 more | Completed | 2010-03past | 1 | |
| Phase 1 | Unnamed | Diabetes | Completed | 2010-10past | 1 | |
| Phase 1 | Unnamed | Diabetes | Completed | 2012-05past | 1 | |
| Phase 2 | Octenidine Dihydrocloride in aqueous solution | Preoperative Skin Preparation | Completed | 2017-08-04past | 1 | |
| Phase 2 | OCT - clear | Preoperative Skin Preparation | Completed | 2017-08-24past | 1 | |
| Phase 1 | Unnamed | Diabetes | Completed | 2009-04past | 1 | |
| N/A | Unnamed | Diabetes Mellitus, Type 1+1 more | Completed | 2008-09past | 1 | |
| N/A | Unnamed | Diabetes Mellitus, Type 1+1 more | Completed | 2009-11past | 1 | |
| N/A | Unnamed | Diabetes Mellitus, Type 2 | Terminated | 2011-06past | 1 | |
| N/A | Unnamed | Uterine Cervical Neoplasms+6 more | Terminated | 2012-03past | 1 | |
| N/A | Unnamed | Diabetes Mellitus, Type 1+1 more | Completed | 2012-05past | 1 | |
| N/A | Unnamed | Diabetes | Completed | 2012-09past | 1 | |
| N/A | Unnamed | Diabetes Mellitus, Type 2+1 more | Completed | 2012-12past | 1 | |
| N/A | Unnamed | Contrast Enhanced Computed Tomography | Completed | 2013-02past | 1 | |
| N/A | Unnamed | Uterine Cervical Neoplasms | Completed | 2013-11past | 1 | |
| N/A | Unnamed | Diabetes | Completed | 2014-08past | 1 | |
| N/A | Unnamed | Acquired Immunodeficiency Syndrome | Completed | 2015-05past | 1 | |
| N/A | Unnamed | Type 1 Diabetes Mellitus | Completed | 2016-02past | 1 | |
| N/A | Unnamed | Uterine Cervical Neoplasms | Completed | 2016-03past | 1 | |
| N/A | Unnamed | Insulin Injections and Lipohypertrophy | Terminated | 2016-08past | 1 | |
| N/A | Unnamed | Uterine Cervical Neoplasm | Terminated | 2017-05past | 1 | |
| N/A | Unnamed | Diabetes Mellitus, Type 1 | Withdrawn | 2017-12past | 1 | |
| N/A | Unnamed | Diabetes | Completed | 2018-04-24past | 1 | |
| N/A | Unnamed | Cervical Neoplasms+1 more | Completed | 2018-12-12past | 1 | |
| N/A | Unnamed | Diabetes | Completed | 2019-04-30past | 1 | |
| N/A | Unnamed | Diabetes | Completed | 2019-06-14past | 1 | |
| N/A | Unnamed | Diabetes Mellitus, Type 2+1 more | Terminated | 2019-08-10past | 1 | |
| N/A | Unnamed | Catheter Related Complication | Completed | 2019-10-14past | 1 | |
| N/A | Unnamed | Microbial Colonization | Completed | 2019-12-24past | 1 | |
| N/A | Unnamed | Diabetes Mellitus, Type 2 | Terminated | 2020-06-12past | 1 | |
| N/A | Unnamed | Indication for Peripheral Intravenous Catheterisation | Completed | 2021-03-12past | 1 | |
| N/A | Unnamed | Diabetes Mellitus, Type 2+2 more | Completed | 2021-04-26past | 1 | |
| N/A | Unnamed | Peripheral Intavenous Catheter Stabilization | Completed | 2021-07-20past | 1 | |
| N/A | Unnamed | Peripheral Intravenous Catheter Stabilization | Completed | 2021-08-23past | 1 | |
| N/A | Unnamed | Covid19+1 more | Withdrawn | 2021-09past | 1 | |
| N/A | Unnamed | Peripherally Inserted Central Catheter | Completed | 2022-01-05past | 1 | |
| N/A | Unnamed | Catheterization | Completed | 2022-01-30past | 1 | |
| N/A | Unnamed | Analgesia+1 more | Completed | 2022-07-22past | 1 | |
| N/A | Unnamed | Healthy+3 more | Completed | 2022-10-24past | 1 | |
| N/A | Unnamed | Healthy Volunteers | Completed | 2023-02-08past | 1 | |
| N/A | Unnamed | Upper Respiratory Infection | Completed | 2023-03-09past | 1 | |
| N/A | Unnamed | Catheter Related Complication+2 more | Completed | 2023-05-22past | 1 | |
| N/A | Unnamed | Plasma Cell Disorder | Completed | 2023-10-25past | 1 | |
| N/A | Unnamed | Effectiveness and Safety of Pre-filled Flush Syringe | Completed | 2023-12-26past | 1 | |
| N/A | Unnamed | Chronic Lymphoproliferative Diseases (CLPD) | Completed | 2023-12-29past | 1 | |
| N/A | Unnamed | Chronic Lymphoproliferative Diseases (CLPD) | Completed | 2024-05-08past | 1 | |
| N/A | Unnamed | Anesthesia+1 more | Completed | 2024-05-28past | 1 | |
| N/A | Unnamed | Acute Leukemia | Completed | 2024-06-29past | 1 | |
| N/A | Unnamed | Cervical Cancer | Completed | 2024-08-26past | 1 | |
| N/A | Unnamed | BD Prevue II for Peripheral Intravenous Catheter Placement | Completed | 2025-09-23past | 1 | |
| N/A | Unnamed | Sepsis | Completed | 2025-10-23past | 1 | |
| N/A | Unnamed | BD SiteRite 9 for VAD Insertion | Completed | 2026-01-09past | 1 | |
| N/A | Unnamed | CRBSI - Catheter Related Bloodstream Infection | Recruiting | 2026-02-28past | 1 |
Valuation
Risk-adjusted NPV
Loading pipeline…
Peer comparison
Cohort check
No peer cohort defined for BDX. Cohorts currently cover gene editing, mRNA, rare-disease gene therapy, and large-cap biotech — more coming soon.